One patient receiving 1 mg/kg of benralizumab intravenously experienced 15 adverse events [chills, headache, asthenia, nausea, dysgeusia, tremors, dizziness, hot flushes, hyperhidrosis, and swelling on day 0, with a decreased white blood cell count (2.3 × 103/μL), decreased neutrophil count (1.1 × 103/μL), and increased C-reactive protein level (1.61 mg/dL) measured on day 1 after dosing]. The gene discussed is CRP; the disease is Hyperhidrosis.